Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Ripple Therapeutics recently announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple’s innovative drug delivery platform.

Ripple Therapeutics is an OBIO® member, an alumnus of our BDSP™ and WiHI programs, a past participant of the CAAP® program, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Federal Government Launches Health Emergency Readiness Canada to Strengthen Preparedness for Future Health Emergencies
Next

IRegained Secures a U.S. Distribution Deal for Their Stroke Rehabilitation Device